Novo Nordisk A/S vs Phillips 66 — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Phillips 66 trades at $212.01 (market cap $83.72B). The key difference: Novo Nordisk A/S is far larger — about 2.6× Phillips 66's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | PSX | |
|---|---|---|
Market Cap | $220.53B | $83.72B |
Sector | Health | Energy |
52-Week High | $71.70 | $208.80 |
52-Week Low | $35.29 | $118.37 |
Enterprise Value | $239.49B | $105.69B |
Dividend Yield | 3.63% | 2.43% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →